USE OF THE DRUG FANCICLOVIR IN THE TREATMENT OF HERPES ZOSTER

Abstract

The study aimed to review the clinical and epidemiological characteristics of herpes zoster, as well as the pharmacokinetic and pharmacodynamic aspects and mechanism of action of famciclovir in the treatment of the condition. This is a narrative, descriptive-exploratory literature review conducted on Google Scholar between April and May 2025, using keywords combined with a Boolean operator. A total of 120 studies were initially identified, of which 16 were selected after applying the inclusion and exclusion criteria. The results indicate that herpes zoster is an infection caused by the reactivation of the varicella-zoster virus, most common in immunocompromised and elderly individuals, presenting symptoms such as pain, fever, and skin lesions. Early treatment with antivirals, preferably within the first 72 hours, is essential to reduce the duration and intensity of symptoms. Famciclovir, a prodrug converted to penciclovir, has good oral bioavailability and acts by inhibiting viral DNA replication, accelerating lesion healing. Its use is recommended for seven days, with a dose of 500 mg, three times a day. It follows that in-depth knowledge of the disease and the drug, combined with prompt action by healthcare professionals in diagnosis and initiation of treatment, is essential for better prognosis and prevention of complications.